Accéder au contenu
Merck

MABN471

ANTI-TAU (MAPT) Antibody

mouse monoclonal, TNT-1

Synonyme(s) :

Microtubule-associated protein tau, Neurofibrillary tangle protein, Paired helical filament-tau, PHF-tau, Tau

Se connecter pour consulter les tarifs organisationnels et contractuels.

Sélectionner une taille de conditionnement

Changer de vue

A propos de cet article

UNSPSC Code:
12352203
eCl@ss:
32160702
NACRES:
NA.41
Clone:
TNT-1, monoclonal
Species reactivity:
mouse, rat, human
Application:
DB, ELISA, IF, IHC, WB
Citations:
3
Service technique
Besoin d'aide ? Notre équipe de scientifiques expérimentés est là pour vous.
Laissez-nous vous aider


Nom du produit

Anti-Tau Antibody, PAD, clone TNT-1, clone TNT-1, from mouse

biological source

mouse

Quality Level

antibody form

purified antibody

antibody product type

primary antibodies

clone

TNT-1, monoclonal

species reactivity

mouse, rat, human

technique(s)

ELISA: suitable, dot blot: suitable, immunofluorescence: suitable, immunohistochemistry: suitable, western blot: suitable

isotype

IgG1κ

NCBI accession no.

UniProt accession no.

shipped in

wet ice

target post-translational modification

unmodified

Gene Information

human ... MAPT(4137)
mouse ... Mapt(17762)
rat ... Mapt(29477)

General description

Tau or Microtubule-associated protein tau (MAPT), also known as neurofibrillary tangle protein and paired helical filament-tau (PHF-tau), is a cytosolic protein that promotes microtubule assembly and stability, and might be involved in the establishment and maintenance of axonal polarity in neurons. Tau binds to and is thought to function as a linker protein between axonal microtubules and neural plasma membrane components. There are multiple isoforms, and the short isoforms allow plasticity of the cytoskeleton whereas the longer isoforms may preferentially play a role in its stabilization. PAD is the phosphatase activating domain, and has been demonstrated to be involved in the inhibition of anterograde, kinesin-based fast axonal transport (FAT) by activating axonal protein phosphatase 1 (PP1) and glycogen synthase kinase 3 (GSK3), independent of microtubule binding. Defects in Tau are thought to be the cause of a number of neurodegenerative diseases, including frontotemporal dementia (FTD), pallido-ponto-nigral degeneration (PPND), Pick disease of the brain (PIDB), corticobasal degeneration (CBD), supranuclear palsy type 1 (PSNP1), Alzheimer disease, and Parkinson disease.
~55 kDa observed. Many isoforms are known to exist between 35-80 kDa An uncharacterized band may be observed in some cell lysates.

Immunogen

KLH-conjugated linear peptide corresponding to human Tau.

Application

Anti-Tau, PAD, clone TNT-1 detects levels of Tau proteins & has been published & validated for use in WB, IHC, IF & ELISA.
Research Category
Neuroscience
Research Sub Category
Neurodegenerative Diseases
Western Blot Analysis: 1 µg/mL from a representative lot detected Tau, PAD in 10 µg of human and mouse cortex tissue lysates.

Immunohistochemistry Analysis: A 1:2,000 dilution from a representative lot detected Tau, PAD in human Alzheimer′s brain tissue.

Immunohistochemistry Analysis: A representative lot from an independent laboratory detected Tau, PAD in normal and Alzheimer′s tissues from entorhinal cortex, hippocampus, inferior temporal gyrus, and superior gyrus of control (Kanaan, N. M., et al. (2011). J Neurosci. 31(27):9858-9868.).

ELISA Analysis: A representative lot from an independent laboratory detected Tau, PAD in recombinant Tau protein (Kanaan, N. M., et al. (2011). J Neurosci. 31(27):9858-9868.).

Physical form

Format: Purified
Protein G Purified
Purified mouse monoclonal IgG1κ in buffer containing 0.1 M Tris-Glycine (pH 7.4), 150 mM NaCl with 0.05% sodium azide.

Preparation Note

Stable for 1 year at 2-8°C from date of receipt.

Analysis Note

Control
rat cortex tissue lysate
Evaluated by Western Blot in rat cortex tissue lysate.

Western Blot Analysis: 1 µg/mL of this antibody detected Tau, PAD in 10 µg of rat cortex tissue lysate.

Other Notes

Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.
Replaces: MAB10417

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.


Still not finding the right product?

Explore all of our products under

ou

Essayez notre Outil de sélection de produits pour affiner vos choix.


Classe de stockage

12 - Non Combustible Liquids

wgk

WGK 1

flash_point_f

Not applicable

flash_point_c

Not applicable



Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents


Contenu apparenté

Alzheimer’s Disease: Amyloid Cascade and Beyond Product Focus


Hayk Davtyan et al.
Vaccine, 35(16), 2015-2024 (2017-03-23)
By the time clinical symptoms of Alzheimer's disease (AD) manifest in patients there is already substantial tau pathology in the brain. Recent evidence also suggests that tau pathology can become self-propagating, further accelerating disease progression. Over the last decade several
Yuki Fujita et al.
STAR protocols, 1(3), 100111-100111 (2020-12-31)
Microglia, the resident immune cells of the central nervous system, accumulate along axons and support neuronal survival during the early postnatal period. Although methods have been developed to isolate microglia or neurons, the procedures for co-culture of these cells can
Michael G Agadjanyan et al.
Molecular neurodegeneration, 12(1), 33-33 (2017-05-06)
The experience from clinical trials indicates that anti-Aβ immunotherapy could be effective in early/pre-clinical stages of AD, whereas at the late stages promoting the clearing of Aβ alone may be insufficient to halt the disease progression. At the same time



Numéro d'article de commerce international

RéférenceGTIN
MABN47104053252850912